Amarin Corp Plc (AMRN)

[Biobillionair]

OB patent 8188146
"Because EPA will compete with AA for incorporation into the Sn2 position of phospholipids, EPA will also reduce the amount of AA incorporated into that position. This is likely to be particularly important in depression, where AA levels are relatively or absolutely abnormally high. EPA itself is a HUFA which can be converted to desirable compounds like prostaglandin I.sub.3 (PGI.sub.3) and prostaglandin E.sub.3 (PGE.sub.3) which have a range of anti-inflammatory and antithrombotic actions which may be particularly useful in neurodegenerative disorders and in depression. The compounds derived from EPA appear to be less potentially harmful than the equivalent compounds derived from AA. Replacement of AA by EPA is therefore likely to be of particular value in all the neurodegenerative disorders described above, where at least part of the damage is attributable to overactive phospholipases which release AA which can then be converted to pro-inflammatory compounds."

EPA:AA ratio can't be denied by the FDA, The USPTO allowed this in the description and the FDA OB'd it.

"fish oil" has nothing to do with Niacin.